ConductScience.org, home

Paper155503

New drugs under clinical evaluation in the United States.

Carter SK. Cancer Chemother Pharmacol, 1978. Cited by 6 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. New drugs under clinical evaluation in the United States. Papers, record 155503. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/155503

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
New drugs under clinical evaluation in the United States.
PubMed
Journal
Cancer Chemother Pharmacol
PubMed
Year
1978
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
6
iCite
Relative citation ratio, by iCite
0.37
iCite
Revised in PubMed
2026-10-10
PubMed

Authors1

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Carter SKS K

Source PubMed

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic AgentsMajor topic
Aldehydes
Altretamine
Antineoplastic Agents, Phytogenic
Carmustine
Cisplatin
Dianhydrogalactitol
Drug Evaluation
Humans
Ifosfamide
Maytansine
Streptozocin
Tegafur
Trichothecenes

Source PubMed

References60

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
15,347,922Clinical trials of a new antitumor polypeptide: neocarzinostatin (NCS).Tohoku J Exp Med1969https://conductscience.org/library/papers/5347922PubMed
21,203,889Clinical studies of Platinum Coordination compounds in the treatment of various malignant diseases.Cancer Chemother Rep1975https://conductscience.org/library/papers/1203889PubMed
34,203,933Platinum coordination complexes in cancer chemotherapy.Naturwissenschaften1973https://conductscience.org/library/papers/4203933PubMed
44,126,381Clinical trials of cis-diamminedichloroplatinum (NSC-119875).Cancer Chemother Rep1973https://conductscience.org/library/papers/4126381PubMed
54,652,589Pharmacologic and antitumor effects of 1,2:5,6-dianhydrogalactitol (NSC-132313).Cancer Chemother Rep1972https://conductscience.org/library/papers/4652589PubMed
65,051,663Results of treatment of malignant tumors with ftorafur.Cancer1972https://conductscience.org/library/papers/5051663PubMed
74,586,957Further experience with hexamethylmelamine (NSC-13875) in the treatment of carcinoma of the cervix.Cancer Chemother Rep1973https://conductscience.org/library/papers/4586957PubMed
84,548,188The chemical and biological effects of cis-dichlorodiammineplatinum (II), an antitumor agent, on DNA.Proc Natl Acad Sci U S A1974https://conductscience.org/library/papers/4548188PubMed
95,631,481Influence of the chemical structure on the biological endency of cytostatic compounds related to dibromomannitol. I. Structure-activity correlations.Arzneimittelforschung1967https://conductscience.org/library/papers/5631481PubMed
105,952,894Cytological studies on the effect of neocarzinostatin on HeLa cells.J Antibiot (Tokyo)1966https://conductscience.org/library/papers/5952894PubMed
115,804,737Toxicological research on substances from Fusarium nivale. 3. The structure of nivalenol and its monoacetate.Tetrahedron Lett1969https://conductscience.org/library/papers/5804737PubMed
126,062,296Metabolic pathway of cytostatic dibromohexitols.Cancer Chemother Rep1967https://conductscience.org/library/papers/6062296PubMed
134,674,442Polyribosomal breakdown in mouse fibroblasts (L-cells) by Fusarenon-X, a toxic principle isolated from Fusarium nivale.Biochim Biophys Acta1972https://conductscience.org/library/papers/4674442PubMed
141,248,396[cis-Diamino-dichloro-platinum (II) in the treatment of otherwise treatment-resistant malignant testicular teratoma (author's transl)].Dtsch Med Wochenschr1976https://conductscience.org/library/papers/1248396PubMed
156,076,607The effect of mannitol-myleran and two new dibromo-hexitols on the metabolic activities of nucleic acids and proteins. I.Biochem Pharmacol1967https://conductscience.org/library/papers/6076607PubMed
165,631,482Influence of the chemical structure on the biological tendency of cytostatic compounds related to dibromomanitol. II. Mechanism of action.Arzneimittelforschung1967https://conductscience.org/library/papers/5631482PubMed
175,054,534Experience with ftorafur treatment in breast cancer.Neoplasma1972https://conductscience.org/library/papers/5054534PubMed
181,203,891Action of Cis-dichlorodiammineplatinum(II) (NSC-119875) at ehe cellular level.Cancer Chemother Rep1975https://conductscience.org/library/papers/1203891PubMed
195,908,739Neocarzinostatin (NSC-69856): an antitumor antibiotic effective against ascitic leukemia L1210 in mice.Cancer Chemother Rep1966https://conductscience.org/library/papers/5908739PubMed
204,447,935A mouse ependymoblastoma as an experimental model for screening potential antineoplastic drugs.Cancer Chemother Rep 21974https://conductscience.org/library/papers/4447935PubMed

See all 60 references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/155503

GET https://conductscience.org/api/papers/v1/155503/references?page=2